Chapter 48: Drugs Affecting Blood Coagulation

Drugs Affecting Blood Coagulation explores pharmacological agents utilized to manage the intricate balance between blood coagulation, the process by which fluid blood forms a solid clot to repair vascular injuries, and clot resolution, the process of dissolving formed clots. Coagulation is initiated by vasoconstriction and platelet aggregation, which forms a temporary plug. The formal clot is then produced via two complex sequences: the intrinsic pathway, activated by Hageman factor inside the vessel, and the extrinsic pathway, activated by tissue thromboplastin outside the vessel. Both pathways culminate in the final step where prothrombin is converted to thrombin, which generates insoluble fibrin threads from fibrinogen. The natural process of dissolving these clots relies on the conversion of plasminogen to plasmin (fibrinolysin), ensuring vessel patency. Drugs intervene to treat two primary classes of coagulation disorders: thromboembolic disorders (excessive clotting, leading to conditions like myocardial infarction, stroke, or pulmonary embolism) and hemorrhagic disorders (deficient clotting, such as hemophilia). Antiplatelet agents, exemplified by aspirin, inhibit platelet adhesion and aggregation, thus preventing the formation of the platelet plug. Anticoagulants interfere with the clotting cascade or thrombin production. Warfarin works by decreasing the liver’s production of vitamin K-dependent clotting factors, while heparin blocks the formation of thrombin from prothrombin. Newer oral agents like rivaroxaban and apixaban function as factor Xa inhibitors. When a clot has already formed, thrombolytic agents (such as urokinase) activate the plasminogen system to dissolve the fibrin threads, a process known as clot resolution. Conversely, for patients with hemorrhagic conditions, antihemophilic agents replace genetically missing clotting factors, and systemic hemostatic agents (like aminocaproic acid) stop bleeding by inhibiting clot breakdown (hyperfibrinolysis). Nursing care for these drugs is critical across the lifespan, involving teaching patients important safety precautions, such as using an electric razor, wearing a MedicAlert notification, and closely monitoring for signs of excessive bleeding and the results of periodic clotting studies (like PT, INR, and APTT).